Case File
efta-02116820DOJ Data Set 10OtherEFTA02116820
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-02116820
Pages
5
Persons
0
Integrity
Extracted Text (OCR)
EFTA DisclosureText extracted via OCR from the original document. May contain errors from the scanning process.
To:
Joseph Thakuria
From:
Lesley Groff
Sent
Mon 1/20/2014 3:12:32 PM
Subject: Re: Jeffrey Epstein-Invoice?
HI Joe...Hope you might get to enjoy a day off? :)
Just following up on the invoice for Jeffrey...let me know how you are doing with it please.
Thanks, Lesley
On Jan 9, 2014, at 5:47 PM, Joseph Thakuria
wrote:
Thanks, Lesley - records are secure but the laptop was out of commission until late
yesterday afternoon unfortunately - making it impossible to check patient labs
remotely.
Joe
On Thu, Jan 9, 2014 at 5:43 PM, Lesley Groff ea>
wrote:
Oh my joe! It is never a dull moment for you!! Thank you so much for your reply
and I will pass it along to Jeffrey. I do hope your records are all secure and laptop
in working order!! Lesley
Sent from my iPhone
On Jan 9, 2014, at 5:36 PM, Joseph Thakuria e
> wrote:
Lesley, sorry for the delay on my end. On top of work, travel and the
holidays,my laptop was out of commission because of problems with
the mgh encryption program used to protect patient data for over 1
week which really set me behind on clinical work - as well as this
invoice.
With some calls over the next few days I should have it wrapped up
by Monday. If not, I'll provide quotes on Monday for what I think
would be worthwhile pursuing and leave placeholders for anything
that still needs follow up on.
Joe
On Thu, Jan 9, 2014 at 7:40 AM, Lesley Groff
wrote:
Hi Joe. Following up with you ... When do you think you might
have an invoice ready for Jeffrey? I would love to be able to give
him an idea.
EFTA_R1_00744703
EFTA02116820
Thanks so very much, Lesley
Sent from my iPhone
On Dec 20, 2013, at 3:01 PM, Joseph Thakuria
wrote:
Hi Lesley,
Sorry about the delay on this. Things have been more
hectic than usual with the holidays and being short-
handed in the hospital and I'm still waiting on a few
things related to the iPS lines and bioinformatics
vendors/platforms. I also have some travel planned.
Can I get this invoice to you and Jeffrey sometime during the week of 12/30
when things will have started to settle down?
Thanks,
Joe Thakuria
On Thu, Dec 12, 2013 at 4:19 PM, Lesley Groff <Ma
wrote:
Hi Joe! Thank you so much for this! I have passed
along to Jeffrey your findings...lets see what he has to
say ...
Thanks again,
Lesley
On Dec 12, 2013, at 3:43 PM, Joseph Thakuria
.P
IMMa
> wrote:
Hi Lesley,
Sorry I've been swamped with clinical
work. We don't have a fellow this month
so I've been in the hospital until late every
day this week.
Realistically I won't be able to provide a
detailed invoice until early next week but
here's the general update:
EFTA_R1_00744704
EFTA02116821
I. I don't think donating sequencing of
patient genomes or exomes will be an
option anymore. I think it will be too
difficult to clear by nigh. And all the
patients I had in mind were seen through
mgh. I'll let you know if this situation
changes.
2. For whole genome sequencing in a clia
lab, I think the best bet is to get this done
directly through Illumina. The cost for this
is $5-10k but I'll run various options by
him. They offer just the raw data as well
as 2 types of analyses. I think he should
do all 3 but I'll include more details in the
invoice. (I'm still discussing with people
from illumina and waiting for some calls
back.)
3. In terms of analysis, since Jeffrey has
said cost is not an issue, the best route in
my opinion would be to analyze across
several of the genomic analyses tools
currently available. Though it's not critical
to analyze across multiple tools, it's a new
enough field that a) they each have their
own pros/cons, b) I don't think the
illumina analyses (both options) provides
enough features for in depth analyses (this
might seem surprising - but shouldn't be -
since they're much more focused on their
sequencing instrumentation business over
analyses tools), and c) comparing results
across the different ones for concordance
is worthwhile. I've honed in on 2-4 I think
are worth using and will tally up the costs
in the invoice.
4. Individualized cell lines: Jeffrey already
has fibroblast cell lines from the skin
biopsy done for the pgp. Induced
pluripotent stem cells (adult stem cells)
can be made from these. They can also be
induced to differentiate into various cell
types including neurons (which would
otherwise, of course, be difficult to obtain
and study in a specific individual). I'm
EFTA_R1_00744705
EFTA02116822
getting itemized costs but getting to iPS
cells costs around $10k and the process
takes about 6 months (because of the
multiple cell passages needed in the
protocol). (Success of course isn't
guaranteed either.)
All this work should fall within or just a
bit over the $30k or so Jeffrey mentioned
over the phone. Payment can be made by
your group directly to the various vendors
once you have that info. As I discussed
with Jeffrey on the phone, I won't
personally accept money and any effort I
contribute to this will be pro bono. And,
this goes without saying, but with respect
to the vendors, these are just suggestions
so Jeffrey should feel free to use other
vendors if he has other preferences.
I'm happy to go through his genome pro
bono using the analyses tools his genomic
data from illumina will get loaded onto
once it's available. I'm also happy to
reassess as well in a year to try and
incorporate any new data that may be
available relevant to his genome. At that
time, there may also be additional data to
generate and analyze from studying his
iPS or other cell lines. On that front, it
may also be interesting to do a genome on
his fibroblast cells (which we currently
have unlike the iPS cells). I wouldn't
expect to get additional medical info from
that but it helps give a handle on
mutations that are present in the fibros
and not him - and later in the iPS cells but
not native cells. (And, therefore, give you
a handle on how accurately these cells will
reflect normal physiology when further
studied.) At some point we can compare
his white blood cell genome to fibroblast
cells to iPS cells and other derived cells.
Some of this hassle, such as needing
multiple vendors for sequencing and
analyses, just comes with the territory of
EFTA_R1_00744706
EFTA02116823
being an early adopter. This will get
cheaper and the process should be more
straightforward over time. And while no
one can guarantee benefit from genome
sequencing, especially in someone
relatively healthy, there is the possibility
of reaping benefit as an early adopter
before others if something medically
actionable is discovered in his data. (We'll
also concentrate our analyses on those 56
genes the ACMG recommended checking
even in healthy individuals).
More to follow and apologies for the
delay on the invoice. You can see I've
been looking into it though and there arc
still a few moving pieces. I'm sorry about
the news on funding patient sequences.
Jeffrey sounded excited about that
possibility. His genomic data should be
interesting though and even if it's of
limited use now, he'll be able to go back
and reanalyze the data in the future as
more is collectively learned in this field.
Best,
Joe
On Dec 11, 2013 5:23 PM, "Lesley
Groff' 1MIIIS.
wrote:
Hi Joe...can you please give me the ETA
for Jeffrey's invoice? I'm sorry to keep
pestering you, but Jeffrey has asked that
I stay on top of this...it is quite
important to him.
Any update would be tremendously helpful.
Thank you,
Lesley
Assistant to Jeffrey Epstein
EFTA_R1_00744707
EFTA02116824
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.